source
- AbCellera halts development of OX40 antibody ABCL575 after phase-1 trialAbCellera announced it will not move ABCL575 beyond phase 1, ending its OX40 program. The phase-1 study met its endpoints, showing a favorable tolerability profile and pharmacokinetics that suppor…
- Coherus Oncology cuts 30% of staff to focus on esophageal cancer comboCoherus Oncology announced another round of layoffs, reducing its workforce by about 30% as it narrows its development program. The cuts follow the presentation of phase 1b data on a combination o…